Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by HighVista Strategies LLC

HighVista Strategies LLC decreased its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 9.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 31,718 shares of the company’s stock after selling 3,410 shares during the quarter. HighVista Strategies LLC owned about 0.06% of Structure Therapeutics worth $1,392,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in GPCR. Squarepoint Ops LLC increased its stake in shares of Structure Therapeutics by 4.5% during the 2nd quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock valued at $567,000 after acquiring an additional 617 shares during the last quarter. Assetmark Inc. increased its stake in shares of Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after acquiring an additional 719 shares during the last quarter. Sandia Investment Management LP acquired a new position in shares of Structure Therapeutics during the 2nd quarter valued at about $39,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after acquiring an additional 1,420 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Structure Therapeutics during the 2nd quarter valued at about $79,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on GPCR. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 23rd. Morgan Stanley began coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. Finally, JMP Securities dropped their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research report on Friday, August 9th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $86.80.

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $33.94 on Tuesday. Structure Therapeutics Inc. has a fifty-two week low of $26.61 and a fifty-two week high of $66.38. The business has a 50 day moving average price of $38.04 and a two-hundred day moving average price of $39.44.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.